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Abstract:  
Background 
In low income countries in Sub-Saharan Africa there are few validated tools to screen 
for common disabling mental disorders such as depression and general anxiety 
disorder (GAD). 
Objectives 
We validated three screening tools: the Shona Symptom Questionnaire for common 
mental disorders (SSQ-14), the Patient Health Questionnaire for depression (PHQ-
9), and the Generalized Anxiety Disorder questionnaire (GAD-7). The study 
participants were attendees at a primary health care clinic in Harare, Zimbabwe.   
Methods 
Consecutive adults aged 18 and above attending the clinic were enrolled over a two-
week period in September 2013. Trained research assistants administered the 
screening tools to eligible participants after obtaining written consent. Participants 
were then interviewed by one of four psychiatrists using the Structured Clinical 
Interview of the DSM-IV (SCID). Performance characteristics were calculated for 
each tool, against the SCID as the gold standard. 
Results 
A total of 264 participants were enrolled, of whom 52 (20%) met the SCID criteria for 
depression alone, 97 (37%) for mixed depression and anxiety and 9 (3%) for anxiety 
alone. Of the 237 where HIV status was known, 165 (70%) were HIV positive. With 
the optimal cutoff of >9, the sensitivity and specificity for the SSQ-14 against a 
diagnosis of either depression and/or general anxiety were 84% (95%CI:78-89%) 
and 73% (95%CI:63-81%) respectively. Internal reliability was high (Cronbach α
=0.74). The optimal cutoff for PHQ-9 was >11, which provided a sensitivity of 85% 
(95%CI:78-90%) and specificity of 69% (95%CI:59-77%) against a SCID diagnosis of 
depression (Cronbach α=0.86). The GAD-7 (optimal cutoff >10) had sensitivity and 
specificity of 89% (95%CI:81-94%) and 73% (95%CI:65-80%) respectively against a 
SCID diagnosis of GAD (Cronbach α=0.87).  
Conclusion 
Screening tools for depression and GAD had good performance characteristics in a 
primary health care population in Zimbabwe with a high prevalence of HIV. These 
can be used for research and also in clinical care to screen patients who may benefit 
from treatment  
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Introduction 
Common mental disorders (CMD) which consist of depression and anxiety disorders 
(Goldberg and Huxley, 1992; Todd et al., 1999) are a leading cause of disability 
globally (Steel et al., 2014). Almost three-quarters of people with CMD in low and 
middle income countries (LMIC) are estimated to be untreated (Lancet Global Mental 
Health Group et al., 2007). This is important because depression and anxiety are 
associated with consequences including lack of work productivity, loss of 
relationships and adverse impacts on development of offspring (Prince et al., 2007). 
Treating depression has been highlighted as a ‘best-buy’ condition globally (WHO, 
2013). This has particular importance in settings with high HIV prevalence because 
detection and treatment of depression and other CMD in people living with HIV 
(PLWH) has the potential to improve adherence to antiretroviral therapy (ART) and 
thus physical outcomes (Abas et al., 2014a; Sin and DiMatteo, 2014). Identifying 
people with CMD using appropriately validated tools is the first step towards 
providing care for CMD (Akena et al., 2012b). Culturally appropriate and user friendly 
validated tools will be helpful for non-specialist workers, including lay health workers, 
to use to assess CMD and to guide clinical care. 
The most widely used tool for screening for common mental disorders in Zimbabwe 
is the Shona Symptom Questionnaire (SSQ-14) (Patel et al., 1997), a non-specific 
tool that screens for possible depressive and anxiety disorders. The SSQ was 
previously validated in a general primary health care (PHC) population at a time 
when HIV prevalence in the general Zimbabwean population was only 5% (Mertens 
et al., 1989). At that time the prevalence of CMD in primary care in Harare was 
reported to be 52% using international criteria (i.e. criteria influenced by external 
western models, also known as etic criteria) and 59% using indigenous criteria (i.e. 
criteria influenced by culture and tradition, also known as emic criteria (Patel and 
Mann, 1997). The current national prevalence of HIV infection is approximately 15% 
(Silverman et al., 2007) and contributes to the high public health burden at PHC level 
(Ferrand et al., 2010). As depression is twice as common in PLWH as in general 
populations and because depression symptoms in PLWH can overlap with HIV 
physical symptoms such as fatigue and appetite disturbance, it is important to 
validate tools for CMD in populations with high HIV prevalence (Tsai, 2014b). In 
LMIC, there are few validated tools for the screening of CMD in populations with a 
high prevalence of HIV (Chibanda et al., 2015a).  
A further reason for validating tools is the emphasis in the last decade on disorder-
specific tools both to improve care pathways for depression and anxiety and for 
research (Chibanda et al., 2014). The Patient Health Questionnaire (PHQ-9) for 
depression, and the Generalized Anxiety Disorder questionnaire (GAD-7) have each 
been found to be suitable screening tools for use at the PHC level in different 
settings (Kroenke and Spitzer, 2002; Kroenke et al., 2001; Monahan et al., 2009; 
Spitzer et al., 2006) but have not been validated in Zimbabwe, particularly in a high 
HIV-prevalent setting. Validating these tools both for  screening and to guide 
treatment algorithms in our setting will enable researchers to better compare their 
findings with other populations receiving treatment in different locations, and to 
understand how depression and anxiety differ by geographic location and the 
composition of the patient population. 
 
The aim of this study was to validate screening tools against a reference standard, 
the Structured Clinical Interview (SCID) of the Diagnostic and Statistical Manual of 
Mental Disorders (DSM-IV), in a population with high prevalence of HIV in urban 
Zimbabwe.  
 
Methods 
Translation of tools 
The first author, a bilingual psychiatrist (DC), carried out the first translation of the 
English versions of the PHQ-9 and GAD-into the local language, Shona. This draft 
Shona version was reviewed by a team including five Lay Health Workers (LHWs) 
working in a primary care mental health program (Chibanda et al., 2011) a bilingual 
clinical psychologist (DM), a bilingual counselor (EpM) and DC. This phase focused 
on ensuring contextual equivalence to the original versions based on their 
understanding and use of local terms for mental distress including kufungisisa 
(thinking too much) (Kidia et al., 2015; Patel and Mann, 1997), kusuwa (to feel sad), 
kusuwisisa (to feel very sad) and mwoyo unorwadza (painful heart) (Abas et al., 
1994). 
The Shona versions of the tools were back-translated into English by a different 
independent language expert. A committee of the first author with the clinical 
psychologist and counselor examined both the original and back translated versions 
and resolved any discrepancies by consensus.  
Tools 
SSQ-14: The Shona Symptom Questionnaire (Patel et al., 1997) was developed and 
validated in Zimbabwe. Most of the items are those common in tools for depression 
worldwide such as sleep disturbance and suicidal thoughts; others are local idioms of 
emotional distress including ‘thinking too much’. Participants are asked if they have 
experienced a list of common mental health symptoms in the past week. Each of the 
14 items are scored dichotomously as yes (1) or no (0) (Patel et al., 1997) 
PHQ-9: The Patient Health Questionnaire, which asks about symptoms over the past 
2 weeks, derives its scoring system from the  DSM-IV criteria for depressive 
disorders. Scores: Minor depression (cutoff: 0-9); moderate/moderately severe 
depression (cutoff: 15-19); severe depression (cutoff: 20-27) assesses symptoms 
of depression as listed in the DSM-IV over the past two weeks. Each of the nine 
items is scored from 0 (not at all) to 3 (nearly every day). It is used as a continuous 
score ranging from 0 (no depressive symptoms) to 27 (all symptoms occurring daily), 
and  as a binary measure, with a cut-point of 10 or greater recommended in the US, 
(sensitivity and specificity for major depression of 88%) (Kroenke and Spitzer, 2002).  
PHQ-2: This screening tool comprises the first two items from the PHQ-9, which 
enquire about loss of interest or pleasure in doing things and feeling down, hopeless 
or depressed (Lowe et al., 2005). The PHQ-2 is often used as an initial brief 
screening for depression, with individuals scoring >3 out of 6 then receiving the full 
PHQ-9 (Lowe et al., 2005; Monahan et al., 2009). 
GAD-7: The Generalized Anxiety Disorder Screen (GAD-7) is a 7-item Likert scale 
that has been validated for the assessment of GAD in both clinical and research 
environments in different cultural settings (Kujanpaa et al., 2014; Lowe et al., 2008; 
Ruiz et al., 2011; Zhong et al., 2015). It consists of 7 items which measure severity of 
symptoms according to reported responses with a maximum possible score of 21 
(Spitzer et al., 2006).The questionnaire enquires about symptoms experienced in the 
last two weeks, such as “feeling nervous, anxious or on edge” and “not being able to 
stop or control worrying” (Lowe et al., 2008).  
Structured Clinical Interview of the Diagnostic Statistical Manual for DSM-IV 
Axis I Disorders (SCID): The SCID is a diagnostic examination used to 
determine major mental disorders. It is administered by a trained mental health 
professional such as a psychologist or psychiatrist in order to make a diagnosis 
based on the Diagnostic Statistical Manual version IV (DSM-IV) (APA, 1994). The 
professional administering the SCID requires clinical skills in the use of open-ended 
questions, diagnostic evaluations and cultural knowledge in a wide range of mental, 
neurological and substance use disorders (Mezzich et al.). In this validation study, 
the SCID was used to make a diagnosis of i) current major depression (mild, 
moderate and/or severe) and ii) GAD. Diagnosis of current major depression was 
based on the following 5 DSM-IV criteria met: A) Five or more symptoms present for 
more than two weeks and represent a significant change from previous functioning; 
B) Symptoms did not meet criteria for a mixed episode; C) Symptoms caused 
significant impairment in social occupational functioning; D) Symptoms were not due 
to the direct effects of a substance; and E) Symptoms were not better accounted for 
by bereavement. For GAD, the following DSM-IV criteria were used: A) Excessive 
anxiety and worry for at least 6 months; B) Difficulty in controlling the worry; C) 
Associated with 3 or more core symptoms; D) The focus of worry is not due to 
concerns of an Axis I disorder; E) The anxiety and worry causes clinically significant 
distress and impairment in functioning; F) The symptoms are not due to substance 
use.  
Training procedures 
Study personnel (four research assistants, six LHWs and four psychiatrists) attended 
a two-week training using a guide initially developed by the authors (DC and RV). 
The research assistants were trained in data collection methods using the socio-
demographic forms and the screening tools during the first week of the training. The 
psychiatrists were trained in the use of the SCID through a discussion forum led by 
DC which involved going through the diagnostic criteria, building consensus on how 
to manage clinically severe cases during the validation, and procedures for ensuring 
fidelity. DC observed the psychiatrists during role-play and the pilot validation where 
each psychiatrist used the SCID to interview 4 patients. The referral pathways for 
participants meeting criteria for major depression and other acute medical conditions 
was that they should be seen by the medical officer first, for assessment, before 
being referred to a tertiary psychiatric facility if needed.  
Study Design and Location 
The validation exercise was carried out as a cross-sectional study at the largest clinic 
in the suburb of Mbare, near the central business district of Harare, Zimbabwe. This 
clinic has a catchment area of over 200,000 with an average attendance of 140 
patients per day. This is a typical primary care clinic in Harare, which is mostly 
staffed by nurses and lay health workers 
Study population and recruitment 
Adults attending the clinic during the two-week study period in September 2013 were 
eligible for recruitment, provided they were aged 18 years or older, were able to give 
written consent and resided in the area. Pregnant women in their last trimester and 
women within the 3-month postnatal period were excluded because for this 
population we had previously validated the Edinburgh Postnatal depression Scale 
(Chibanda et al., 2009), as were those who were unable to understand the purpose 
of the study.  
Sample size 
We aimed to recruit a representative sample of patients from a primary care clinic. A 
minimum of 75 participants who scored positive on the reference standard for 
depression (the SCID) and 75 who score negative on the SCID, would provide good 
precision for performance indicators: sensitivity of 91% (95%CI:82-96%); specificity 
of 80% (95%CI:69-88%), positive predictive value (PPV) of 82% (95%CI:72-90%) 
and negative predictive value (NPV) of 90% (95%CI:80-96%). We increased the 
sample size to 264 to allow for stratification by HIV status, assuming HIV prevalence 
of 60% in the clinic population (Ferrand et al., 2010) 
The Validation Procedure:  
Stage 1: Each morning during the study period, an appointed research assistant   
obtained the register of all adult patients waiting to be seen. The research assistant 
randomly selected clinic attendees based on a computer-generated random number 
sequence. Fifteen randomly selected participants were invited at one time to a quiet 
and private space where eligibility was determined. Informed written consent was 
sought from all those eligible. The six research assistants administered the SSQ-14, 
PHQ-9, and GAD-7 tools to participants according to a random order determined by 
DC and also collected socio-demographic information such as age, gender, HIV 
status, marital and employment status. The interviews took 20-30 minutes and were 
conducted in a quiet space designated for the study team. 
Stage 2: Following administration of the screening tools, participants were referred to 
one of four psychiatrists who conducted the SCID. The psychiatrists were blinded to 
the screening data. The SCID interview lasted 30 to 60 minutes in a private and quiet 
room. All those meeting criteria for DSM IV psychiatric condition were further 
assessed for treatment and referral to the psychiatric hospital.  
Data collection and management 
All data was double entered onto a password-protected database using Stata 
(version 13). No participant identifiable information was entered while ethics and 
confidentiality for all participants was respected in accordance with the medical 
research council of Zimbabwe 
Analysis 
The performance of each tool against the reference standard (SCID) was as follows: 
i) SSQ-14 against any CMD of depression and/or anxiety; ii) SSQ-14 against 
depression; iii) PHQ-9 against depression; iv) PHQ-2 against depression; v) GAD-7 
against anxiety. For each association, we estimated the sensitivity, specificity, 
positive predictive value (PPV) and negative predictive value (NPV) for different cut-
points. For SSQ-14, PHQ-9 and GAD-7, the cut-point was chosen to provide a good 
balance of sensitivity and specificity. The PHQ-2 is intended for using as a screening 
tool prior to confirmation by PHQ-9, so high sensitivity was chosen for this tool. 
Results were presented in the form of a ROC curve which plots the true positive rate 
(sensitivity) against the false positive rate (1-specificity) (Pepe, 2003). The area 
under a ROC curve (AUC) quantifies the overall ability of the test to discriminate 
between those individuals with the outcome and those without the outcome. An AUC 
of 0.8 or above is ‘good’. The optimal cut-point was selected to have a good balance 
of sensitivity and specificity, except for the PHQ-2 where the tool is used solely as a 
screening tool to be confirmed with PHQ-9, so high sensitivity was more important. 
Internal reliability was estimated using Cronbachs’ α. All analyses were conducted 
using Stata (version 13).  
 
Results 
Of the 264 participants, 208 (79%) were female, 157 (60%) were married, and 199 
(75%) had completed secondary school education (Table 1). HIV serostatus was 
known for 237 (90%) participants, of whom the majority (70%, n=165) were HIV 
positive, and 151 (92%) of these were on ART. The prevalence of any CMD by SCID 
was high (n=158, 60%), with 52 participants (20%) meeting the SCID criteria for pure 
depression, 97 (37%) for mixed depression and anxiety and 9 (3%) for pure anxiety.  
CMD prevalence by SCID was substantially higher among PLWH than those without 
HIV (67% vs 39%; p<0.001).  Prevalence of any CMD was significantly higher among 
PLWH than those without HIV (69% vs 41%; p<0.001). 
  
Performance of the SSQ-14 against SCID diagnosis of any CMD (depression 
and/or anxiety) 
An SSQ-14 cutoff of  >9 provided the highest proportion of participants correctly 
classified comparing with SCID diagnosis of any CMD (82%). With this cutoff, 
sensitivity was 84% (95%CI:78-89%) and specificity was 73% (95%CI:63-81%; Table 
2; Figure 1). The ROC curve for the performance of SSQ-14 against any CMD gave 
an AUC of 0.86 (95%CI 0.81-0.90; Figure 2) and showed good internal consistency 
(Cronbach’s alpha=0.74). With this cutoff of >9 the prevalence of CMD was 61% 
(95%CI:55-67%) with PPV 82% (95%CI:75-88%) and NPV 75% (95%CI:66-83%). 
Among PLWH, the prevalence of CMD by SSQ-14 was 68% with PPV/NPV of 
89%/74%, while among those without HIV the prevalence was 51% with PPV/NPV 
62%/80%. Sensitivity and  specificity were higher among PLWH than HIV negative 
participants (sensitivity=88% vs. 77%; specificity 76% vs. 67%; Table 2; Figure1).  
 
Performance of the SSQ-14 against SCID diagnosis of depression  
Similar results were seen for the SSQ-14 against a diagnosis of depression (pure 
depression or depression mixed with anxiety), with sensitivity of 86% (95%CI:80-
92%), specificity 70% (95%CI:61-79%), PPV 79% (95%CI:72-85%) and NPV 79% 
(95%CI:70-87%). The tool performed better among PLWH than HIV negative 
participants (sensitivity=87% vs. 82%; specificity 71% vs. 66%; Table 2; Figure 1).  
 
Performance of the PHQ-9 against SCID diagnosis of depression  
 
For the PHQ-9, the optimal cutoff of >11 provided sensitivity for detecting depression 
(pure depression or depression mixed with anxiety) of 85% (95%CI:78-90%) and 
specificity of 69% (95%CI:59-77%; Table 2). The ROC curve gave an AUC of 0.84 
(95%CI 0.79-0.88). The PPV was 78% (95%CI:71-84%) and NPV was 77% 
(95%CI:68-85%). The sensitivity was higher among PLWH than HIV negative 
individuals (88% vs. 79%), but the specificity was similar by HIV status (71 vs. 73%; 
Table 2). Internal consistency was very good (Cronbach’s alpha=0.86)   
 The PHQ-2 had high sensitivity as a screening tool with a cutoff of >2 (sensitivity 
91%; 95%CI 86-95%) although this had low specificity (40%; 95%CI:31-50%; Figure 
1; Table 2), and this chosen as the optimal cut-point as individuals screening positive 
would have a confirmatory test with PHQ-9. 
 
Performance of the GAD-7 against SCID diagnosis of anxiety  
A cutoff of >10 for GAD-7 gave a sensitivity of 89% (95%CI:81-94%) and specificity 
of 73% (95%CI:65-80%; Table 2; Figure 1), for detecting anxiety (pure anxiety or 
depression mixed with anxiety), correctly classifying 79% of participants. The PPV 
was 69% (95%CI:60-76%) and NPV was 91% (95%CI 84-95%). The ROC curve 
gave an AUC of 0.90 (95%CI 0.87-0.94; Figure 3). Again, the sensitivity was higher 
among PLWH than HIV negative individuals (94% vs. 75%) but specificity was lower 
among PLWH (68% v 80%; Table 2; Figure 1). There was very good internal 
consistency (Cronbachs α=0.87).  
 
 
Discussion 
As interventions for CMD are scaled-up in sub-Saharan Africa, the need for user-
friendly validated tools is critical (Abas et al., 2014b). We recently highlighted the 
absence of validated tools in clinical trials of psychological interventions for PLWH in 
LMIC (Chibanda et al., 2015b). This study demonstrates the feasibility of validating a 
series of screening tools for CMD among populations with high prevalence of PLWH 
in a resource limited setting. We found the three screening tools (SSQ-14, PHQ-9, 
and GAD-7) have good internal consistency and performance characteristics.  
 
All the tools validated in this study were developed in a Western setting (Kroenke et 
al., 2001; Lowe et al., 2008) except for the SSQ-14, which was developed in 
Zimbabwe using cross-cultural methods in an era of low HIV prevalence (Patel et al., 
1997). The SSQ-14 had been previously validated with a cutoff of >8 (Patel et al., 
1997) but this cut-off provided relatively low specificity (57%) in our current setting 
with high HIV prevalence setting. Using a cutoff of >9, we see improved specificity 
(70%) with little loss of sensitivity (94% vs. 85%). Overall, 74% of participants were 
correctly classified with a cutoff of >8, compared with 79% using a cutoff of >9 and 
we recommend use of the higher cutoff in this setting. The high prevalence of CMD 
in this population gives stability to the PPV, which is influenced by the prevalence of 
the condition under study. Most true positives according to SCID are detected (84%) 
with a cutoff of >9 in the total sample and among PLWH (88%).   
 
Our chosen cut-off of >11 for the PHQ-9 is within the range (8-11) reported as 
acceptable for detecting depression in a recent meta-analysis on optimal cut-off 
scores for diagnosing depression with the PHQ-9 (Manea et al., 2012). A recent 
study from South Africa recommended a cut-off of >10, although this gave a low 
sensitivity of 49% and a specificity of 94% (Bhana et al., 2015).  
 
The PHQ-2 has been recommended as an initial screen before administering the full 
PHQ-9 (Lowe et al., 2005; Monahan et al., 2009) and we recommend a cutoff of >2 
which has high sensitivity (91%), assuming that a confirmatory test follows.  
 
The validation of the SSQ-14, PHQ-9, and GAD-7 among PLWH is consistent with 
our earlier work which reveals the need to utilize culturally sensitive and adequately 
validated tools in LMIC, particularly among PLWH (Abas et al., 2014b). We utilized a 
multi-disciplinary team consisting of medical professionals, experts in the English and 
Shona (indigenous language) as well as lay health workers who have a deep cultural 
understanding of local concepts of depression at community level to ensure 
acceptability of our final validated tools. Furthermore, the use of clinicians to 
administer the reference standard ensured accuracy in diagnosis by reducing the  
risk of misclassification of CMD due, for example, to HIV-associated cognitive 
impairment, and general physical symptoms associated with HIV infection as has 
been reported  (Tsai, 2014a). Our validated tools have shown good internal 
consistency, high sensitivity and acceptable specificity.  
 
Prevalence of HIV is increasing in sub-Saharan Africa due to decreases in mortality 
as access to antiretroviral therapy is scaled up, and strength of our study was the 
focus on performance of scales among PLWH. The results will enable local 
researchers developing epidemiological and intervention studies to work with more 
accurate cut-off scores with PLWH. The tools showed consistently better 
performance among PLWH than HIV negative individuals, because of the high 
prevalence of CMD in the HIV positive group. A limitation of our study is that we had 
relatively low precision to evaluate the tools in people living without HIV. 
 
While evidence supporting the use of LHWs is growing (van Ginneken et al., 2013) 
the need to build capacity in the area of intervention development and particularly 
validation of culturally sensitive tools for use by LHWs has been emphasized (Akena 
et al., 2012b). In sub-Saharan Africa, where literacy rates can be extremely low, 
there is a need to consider the validation of visual screening tools such as has been 
the case in Uganda, where a visual screening tool for depression was found to have 
good internal consistency (Akena et al., 2012a). Limitations of our study include the 
absence of data on stages of HIV disease, CD4 count, viral load and type of HAART 
as these can affect CMD manifestation in PLWH (Akena et al., 2010; Evans et al., 
2002; Pecoraro et al., 2015). Performance of tools for depression could potentially 
vary by other factors such as education and gender which we have not investigated 
in this paper. There has been concern about using standard tools when screening for 
depression in PLWH due to possible overlap of somatic symptoms with HIV-disease 
symptoms, and due to the difficulty in separating some depression-related symptoms 
from symptoms caused by HIV-associated neurocognitive disorder. This will be a 
matter of investigation for a further study.   
 
Conclusion 
We have successfully validated different tools for common mental disorders in a high 
HIV prevalent setting, showing good performance but with slightly different cutoffs 
compared with those used in low HIV prevalence settings. Although our findings can 
be generalized to similar settings in Zimbabwe and in the southern African region 
where HIV prevalence is high in health service users,  there is still need for further 
research in sub-Saharan Africa to  develop and validate tools that are user-friendly 
for LHWs to use in everyday practice. 
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Figure 1: Sensivitiy and specificity by tool and HIV status 
 
Figure 2: ROC curve for SSQ against CMD - depression and/or anxiety by SCID  
(n=264) 
 
 
  
Table 1.  Characteristics of study participants 
Characteristic All participants 
(n=264) 
 N % 
Gender      
Male 56 21.2% 
Female 208 78.8% 
Age group   
<30 58 22.8% 
30-39 91 35.8% 
40-49 72 28.4% 
50+ 33 13.0% 
Marital status    
Married/partnered 157 59.5% 
Divorced/widowed 52 19.7% 
Single 55 20.8% 
Education    
Primary or less 65 24.6% 
Secondary or more 199 75.4% 
Current employment status   
Unemployed 112 42. 4% 
Permanent full time/part time  26 9.9% 
Casual/self-employed 126 47.7% 
Main income source   
Own business/salary 149 56.4% 
Partner/family 98 37.1% 
No income 17 6.4% 
Suffer from chronic illness  120 45.5 
Negative life eventin last six months  237 89.8% 
HIV prevalence
1
 165 69.6% 
Prevalence of common mental disorders using the reference standard   
SCID-pure depression 52 19.7% 
SCID- pure anxiety
 
 9 3.4% 
SCID-mixed depression/anxiety 97 36.7% 
SCID –any CMD (SCID depression and/or anxiety) 158 59.8% 
Prevalence of common mental disorders using the tools   
SSQ-14 score (median and IQR) 9 7-11 
SSQ >= 9 162 61.4% 
PHQ-9 score (median and IQR) 13 8-18 
PHQ-9 >=11 162 61.4 
PHQ-2 score (median and IQR) 3 2-5 
PHQ-2 >=2 205 77.7% 
GAD-7 score (median and IQR) 10 6-15 
GAD-7>=10 137 51.9% 
 
 
 
 
 
 
                                                 
1 Of the 237with known HIV status 
 
 
 
 
Table 2. Sensitivity and specificity of tools, overall and by HIV status 
1 CMD=any SCID pure depression, pure anxiety or mixed depression/anxiety. 
2 Pure Depression or mixed depression/anxiety    
3 Pure Anxiety or mixed depression/ anxiety 
 
 
 
 
 
Highlights 
 
 Validation of screening tools in sub-Saharan Africa is an important step 
towards addressing the treatment gap for common mental disorders. 
 Special consideration is needed when validating tools in a high HIV prevalent 
setting 
 It is possible to validate multiple tools in a high HIV prevalent setting in low 
resource settings. 
  
Tool  Cutpo
int 
Referen
ce 
standar
d 
All participants HIV positive 
participants 
HIV negative 
participants 
   Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Sensiti
vity 
(95% 
CI) 
Specifi
city 
(95% 
CI) 
Sensiti
vity 
(95% 
CI) 
Specifi
city 
(95% 
CI) 
SSQ-
14 
>=9 SCID -
any 
CMD
1
 
84% (78-89%) 73% (63-81%) 88% 
(80-
93%) 
76% 
(63-
87%) 
77% 
(58-
90%) 
67% 
(50-
80%) 
SSQ-
14 
>=9 SCID-
depressi
on
2
  
86% (79-91%) 70% (61-79%) 87% 
(80-
93%) 
71% 
(57-
82%) 
82% 
(63-
94%) 
68% 
(52-
81%) 
PHQ-9  >=11 SCID-
depressi
on 
2
 
85% (78-90%) 69% (59-77%) 88% 
(81-
94%) 
71% 
(57-
82%) 
79% 
(59-
92%) 
73% 
(57-
85%) 
PHQ-2  >=2 SCID-
depressi
on
2
    
91% (86-95%) 40% (31-50%) 92% 
(85-
96%) 
25% 
(15-
39%) 
93% 
(76-
99%) 
59% 
(43-
74%) 
GAD-7 >=10 SCID-
anxiety
3
 
89% (81-94%) 73% (65-80%) 94% 
(86-
98%) 
68% 
(57-
78%) 
75% 
(68-
90%) 
80% 
(68-
88%) 
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